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Background: The ectodomain of the Adenovirus 
E3/49K membrane protein is secreted after 
proteolytic processing.. 
Results: Ectodomain cleavage and secretion is 
regulated by sorting motifs in the cytoplasmic tail 
and strongly reduced by matrix-metalloprotease 
inhibitors. 
Conclusion: E3/49K shedding is mediated by 
matrix metalloproteases at the cell surface. 
Significance: Insight into the mechanism of 
E3/49K secretion enables improved production 
and further exploitation as immunomodulator 
for therapy. 
 
ABSTRACT  
The E3 transcription unit of human species C 
adenoviruses (Ads) encodes immunomodulatory 
proteins that mediate direct protection of infected 
cells. Recently, we described a novel 
immunomodulatory function for E3/49K, an E3 
protein uniquely expressed by species D Ads. 
E3/49K of Ad19a/Ad64, a serotype that causes 
epidemic keratokonjunctivitis, is synthesized as a 
highly glycosylated type I transmembrane protein 
that is subsequently cleaved resulting in secretion 
of its large ectodomain (sec49K). Sec49K binds to 
CD45 on leukocytes, impairing activation and 
functions of NK cells and T cells. E3/49K is 
localized in the Golgi/trans-Golgi-network (TGN), 
early endosomes and on the plasma membrane, yet 
the cellular compartment where E3/49K is cleaved 
and the protease involved remained elusive. Here 
we show that TGN-localized E3/49K comprises 
both newly-synthesized and recycled molecules. 
Full-length E3/49K was not detected in late 
endosomes/lysosomes but the C-terminal fragment 
accumulated in this compartment at late times of 
infection. Inhibitor studies showed that cleavage 
occurs in a post-TGN compartment and that 
lysosomotropic agents enhance secretion. 
Interestingly, the cytoplasmic tail of E3/49K 
contains two potential sorting motifs, YxxΦ and 
LL that are important for binding the clathrin 
adaptor proteins AP-1 and AP-2 in vitro. 
Surprisingly, mutating the LL motif, either alone or 
together with YxxΦ, did not prevent proteolytic 
processing, but increased cell surface expression 
and secretion. Upon Brefeldin-A treatment cell 
surface expression was rapidly lost, even for 
mutants lacking all known endocytosis motifs. 
Together with immunofluorescence data, we 
propose a model for intracellular E3/49K transport 
whereby cleavage takes place on the cell surface 
by matrix-metalloproteases.  
 
INTRODUCTION  
Human adenoviruses (Ads) comprise more than 60 
different types that are classified into 7 species, A-
G (1,2). In immunocompetent individuals Ads 
typically induce self-limiting infections associated 
with acute disease, while in a fraction of cases 
persistent infections may ensue (3,4). In 
immunocompromised patients, diseases tend to be 
severe or even fatal, demonstrating the significant 
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impact of the immune system on Ad disease. 
While overlapping, the disease pattern differs 
between Ad species. Species A, F and G are 
associated with gastroenteritis while species B, C, 
and E are mainly associated with respiratory 
diseases and species D with eye diseases (3). 
However, only rarely has a clear link been 
demonstrated between a defined disease and 
infection with specific Ad types. One such case is 
epidemic keratoconjunctivitis (EKC) (5), a highly 
contagious and severe eye disease that presents 
with typical subepithelial corneal infiltrates of 
dendritic cells, keratocytes and inflammatory 
leukocytes that may persist for months or years (5-
7). Only a few Ad types of species D, Ad8, Ad19a 
(recently renamed Ad64 (2), Ad37, Ad53, Ad54 
and Ad56 cause this disease, yet the reasons for 
this association remain obscure (8-10). As the 
cellular receptors of the EKC-causing (sero)types 
are widely distributed or ubiquitous (11-13), 
differential receptor usage does not explain the 
specific pathogenesis in the eye. Hence, the 
disease may be due to selective events occurring 
post-attachment, e.g. differential triggering of 
innate and adaptive immune responses (3,14-16) 
or their differential manipulation by specific 
immunomodulatory functions encoded in the early 
transcription unit 3 (E3) of EKC Ads (14,17).  
The E3 region is not required for Ad replication 
in vitro, yet is preserved in all human Ads, 
indicating an important role for virus-host 
interaction in vivo (18). Supporting this view, 
previous studies of species C Ad E3 proteins 
unraveled multiple immune evasion mechanisms 
that seem to facilitate persistent infections 
(3,14,18,19). E3 is one of the most divergent 
regions of the Ad genome (17,20-22), differing 
considerably in size, gene composition and 
sequence both between and within Ad species. 
Species D Ads have the largest E3 region 
encoding eight open reading frames (ORFs). Of 
these, the E3/10.4K, 14.5K and 14.7K ORFs are 
present in all species and down-regulate various 
apoptosis receptors from the cell surface or affect 
their signaling (3,14,23,24), while E3/19K is only 
present in Ads of species B-E that do not cause 
gastroenteritis. E3/19K retains MHC class I 
molecules (MHC-I) and MHC-I related chain A 
and B in the endoplasmic reticulum (ER), thereby 
suppressing recognition by cytotoxic T-
lymphocytes (25-27) and natural killer (NK) cells 
(28,29). A few E3 genes are unique to a particular 
species and hence may allow for species-specific 
immunomodulation and differential disease 
outcome (3,17,18,30,31). However, with the 
exception of E3/49K (32) no immune evasion 
function for species-specific E3 proteins has been 
identified to date.  
The E3/49K ORF was initially identified in the 
E3 region of the EKC-causing Ad19a/Ad64 (33). 
This gene is unique for species D Ads and all 
species D Ads tested expressed the corresponding 
protein (34), implicating it in their pathogenesis. 
Interestingly, E3/49K (also called CR1-β) is the 
protein with the highest frequency of amino acid 
substitutions, presumably due to a recombination 
hotspot (22). E3/49K is a highly glycosylated type 
I transmembrane protein that migrates with an 
apparent molecular weight (mr) of 70-100 kDa and 
as such is by far the largest E3 protein. Ad19a 
E3/49K is abundantly synthesized in the early 
phase of infection but continues to be produced in 
the late phase albeit only with immature 
carbohydrates. The sequence of the extracellular 
domain revealed three internal repeats designated 
conserved region 1-3 (CR1-3) that are predicted to 
form immunoglobulin-like domains. Interestingly, 
similar domains seem to be present in some other 
E3 proteins and members of the RL11 family in 
cytomegalovirus (33,35,36). E3/49K exhibits a 
novel processing pathway for E3 proteins.  
Approximately 1 h after synthesis it is cleaved by 
an unknown cellular protease N-terminal to the 
transmembrane domain generating a small 
membrane-integrated 12-14 kDa C-terminal 
fragment and a large ectodomain (sec49K) that is 
secreted or shed (32,37). Sec49K is the first 
secreted E3 protein and the first secreted 
adenovirus protein known to date. Unlike the other 
E3 proteins that act directly on infected cells, 
sec49K can affect host immune functions over a 
distance by targeting leukocytes via binding to the 
cell surface phosphatase CD45. This impairs 
activation of CD4 T cells and NK cells, inhibiting 
cytokine production and cytotoxicity, respectively, 
most likely by modulating signal transduction. 
Thus for the first time an immunomodulatory E3 
function of a non-species C adenovirus was 
described. As species D-based Ad vectors have 
considerable potential for applications in humans 
(38,39), further characterization of E3/49K would 
be of great importance. 
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At steady state, the Ad19a E3/49K protein is 
predominantly localized in the Golgi/trans-Golgi-
network (TGN) and in early endosomes (EEs), but 
is also present on the cell surface (32,37). Its 19-
residue cytoplasmic tail contains two conserved 
putative sorting motifs: a tyrosine-based YxxΦ 
motif (x: any amino acid; Φ: a bulky hydrophobic 
amino acid), and a dileucine-based (LL) motif (see 
Fig. 3) that may be involved in targeting E3/49K 
to these compartments (40-42). Such motifs are 
recognized by adaptor proteins (AP-1 to AP-5), 
thereby recruiting transmembrane cargo into 
transport vesicles at various locations within the 
cell (43). AP-1 to AP-3 can associate with the coat 
protein clathrin, e.g. in endosomes, at the plasma 
membrane or at the TGN, determining trafficking 
pathways and ultimately the distribution of 
membrane proteins (41,44,45). However, it 
remains elusive what role these motifs may have 
in E3/49K trafficking, proteolytic processing and 
secretion. It is also unclear which protease is 
involved and in which cellular compartment 
cleavage takes place.  
Here we show that the cytoplasmic tail of 
E3/49K binds to AP-1 and AP-2 in vitro in a 
motif-dependent fashion. Mutation of the LL motif 
alone or in combination with YxxΦ profoundly 
increased E3/49K cell surface expression and 
sec49K secretion. Surprisingly though, proteolytic 
cleavage was independent of their presence, 
suggesting that it requires only the default 
pathway and is executed rather inefficiently by a 
sheddase of the matrix metalloprotease family at 
the cell surface. While most E3/49K was recycled 
to the TGN, a minor fraction may be sorted to 
lysosomes where C-terminal fragments undergo a 
second cleavage. Based on these data we propose 
a model for E3/49K trafficking that has 
implications for sec49K production and function. 
 
EXPERIMENTAL PROCEDURES 
Chemicals – Chloroquine, leupeptin, brefeldin A 
(BFA), bafilomycin A1, tunicamycin and 
monensin were purchased from Sigma, 
cycloheximide from Calbiochem and ammonium 
chloride from Merck.  
 
DNA constructs - The expression vector pSG5-
E3/49K encoding wild type E3/49K has been 
described previously (37). Fragments encoding 
mutations in the cytoplasmic tail of E3/49K were 
amplified by PCR using the following primers, all 
given in 5’-3’ direction. Universal sense primer: 
ggtacaatcatcaaggaacccagag; individual antisense 
primer: LL/AA: gtccagatctggatccgtcttagtaagagaa-
gctggctgctgggtctaccata;∆CT:gtccagatctggatccgtctt
aacgcttgcggcagcagatgtagc; Y/A: gtccagatctggatc-
cgtcttagtaagagaagctgagtagtgggtctaccatatgattggctgc
cctgggacgctt; YLL/AAA: gtccagatctggatccgtctta-
gtaagagaagctggctgctgggtctaccatatgattggctgccctggg
acgctt. PCR fragments were cloned into the pSG5-
E3/49K vector using BglII restriction sites 
(underlined) in the E3/49K coding sequence and 
the pSG5 multiple cloning site. Correct 
construction was verified by sequencing both 
strands of the E3/49K ORF. In the ∆CT construct, 
the stop-anchor sequence RKR was retained to 
ensure correct orientation and stable membrane 
integration. 
 
Monoclonal antibodies (mAbs) and antisera - 
The polyclonal rabbit antiserum R25050 (anti-
49Kct) raised against the C-terminal 15 amino 
acids of E3/49K was described previously (34) as 
were the polyclonal rabbit antiserum R48 (anti-
49K-N) and the rat monoclonal antibody (mAb) 
4D1, both raised against amino acids 20-382 of 
Ad19a E3/49K (32). The sheep and rabbit antisera 
against TGN46 were published previously (77). 
The mouse mAb 2D5 against LAMP-2 (46) was a 
kind gift of A. Hasilik (University of Marburg, 
Germany).  
 
Viruses, infection, transfection and cell culture - 
For growing Ad19a stocks, for plaque assays and 
most infection experiments the lung epithelial 
carcinoma cell line A549 (ATCC CCL-185) was 
used. For some infection experiments primary 
human foreskin fibroblasts (SeBu) were employed 
(24). Both cell types were maintained in 
Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 100 U/ml penicillin, 0.1 mg/ml 
streptomycin (Invitrogen) and 10% fetal calf 
serum (Roche Diagnostics). In general, infection 
was performed using five plaque forming units 
(pfu) Ad19a per cell for 1 h. Then the virus was 
removed and this time point was defined as the 
start of infection.  
Generation of A549 cells stably expressing 
mutant E3/49K molecules was done as for the 
cells expressing wild-type E3/49K (37) using the 
calcium phosphate method essentially as described 
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(47) except that the glycerol shock was omitted. 
Briefly, three 10 cm diameter dishes of A549 cells 
were co-transfected with 20 µg each of the 
relevant pSG5-E3/49K construct and 2 µg of the 
pSV2-neo
r
 plasmid conferring G418 resistance as 
described (48). The next day, the medium was 
changed and two days later cells were split 1:4 or 
1:8 into medium containing 1 mg/ml G418. After 
10-14 days ~30 G418-resistent clones were 
isolated using cloning cylinders and maintained in 
medium containing 1 mg/ml G418. For transient 
transfection of A549 cells principally the same 
protocol was followed except that 6 cm-diameter 
dishes of cells were incubated with 0.5 ml 
Calcium-DNA precipitate (5-8 µg pSG5 
construct).  
 
Metabolic labeling, immunoprecipitation and 
SDS-PAGE - Labeling of A549 cells with [
35
S]-
methionine alone or in combination with [
35
S]-
cysteine (Promix, GE Healthcare), 
immunoprecipitation and sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) 
were performed as described previously (25,37) 
using 
14
C-methylated proteins as molecular weight 
markers (GE Healthcare). Radioactive bands were 
quantified using a Storm 860 Molecular Imager 
(Molecular Dynamics).  
 
Immunofluorescence - Subconfluent layers of 
A549 or primary SeBu cells were grown on glass 
coverslips and processed for immunofluorescence 
exactly as described (37,49). Secondary antibodies 
were purchased from Dianova (Germany): donkey 
anti-mouse IgG- fluorescein isothiocyanate 
(FITC), donkey anti-rabbit IgG-FITC, donkey 
anti-mouse-rhodamine Red-X, donkey anti-rat-
Texas Red, donkey anti-sheep-rhodamine Red-X 
or from Life Technologies: goat anti-rat IgG 
Alexa488, goat anti-sheep IgG Alexa594, goat 
anti-rabbit IgG Alexa633. Mounted cells were 
analyzed with a laser scanning confocal 
microscope (Leitz DM IRB; scanner, Leica TCS 
NT) Images shown are single sections in z. 
 
Flow cytometry - Flow cytometry (FACS) was 
carried out essentially as described (50), with 
some modifications (49). As E3/49K is sensitive to 
trypsin-mediated proteolysis cells were washed 
with PBS and then detached with 1 mM EDTA in 
PBS. 300,000-500,000 cells were incubated with 1 
µg purified or 100 µl undiluted supernatant of 
mAb 4D1 directed to the ectodomain of Ad19a 
E3/49K. Following several washes in FACS buffer 
cells were incubated with 50 µl FITC-labeled 
(Sigma, 1:50) or Alexa Fluor 488-labelled goat 
anti-rat IgG (Invitrogen, 1:100). Subsequently, 
5000 cells were analyzed in a FACScan or 
FACSCalibur (BD Biosciences).  
 
Detection of secreted E3/49K using the 
quantitative FACS-based binding assay - The 
amount of sec49K in the supernatant of cells was 
quantitatively determined by binding to CD45
+
 
Jurkat T cells as a read-out (32).  WT or mutant 
E3/49K expressing A549 cell clones were 
incubated for 15-18h with the broad spectrum 
matrix metalloprotease (MMP) inhibitors BB-94 
(5µM; Tocris Biosciences) and CT1746 (51) 
(10µM), kindly provided by D. Edwards, 
University of East Anglia, Norwich, UK. The 
more selective inhibitor GI254023X (52), 
targeting primarily ADAM10 and less well 
ADAM17, was kindly provided by A. Ludwig, 
RWTH Aachen, Germany and was used as 5µM. 
All MMP inhibitors were solubilized in DMSO, 
hence data from inhibitor-treated cells were related 
to those of mock-treated cells using the same final 
concentration of DMSO (0.1%). For detection of 
sec49K in supernatants of mutant cell lines cells 
were grown in 6 cm dishes or 6-well dishes for 4 
days. Cell supernatants were harvested and 
centrifuged for 10 min at 1,500g prior to 
incubation with Jurkat cells or storage at 4°C. 
Subsequently, cells were treated with 
trypsin/EDTA to determine the number of cells in 
the culture. Data were collated from at least two 
independent supernatants and four independent 
FACS measurements. Production of sec49K was 
calculated as mean fluorescence intensity of 
sec49K binding/10
6 
producer
 
cells. The different 
expression level was taken into account by relating 
this value to the intracellular expression after 5 h 
of BFA treatment.  
 
Surface plasmon resonance - In order to test for 
the capacity of the cytoplasmic tail of E3/49K to 
bind the clathrin adaptor complexes AP-1 and AP-
2 peptides comprising the WT cytoplasmic tail and 
mutant forms of E3/49K with mutations of the 
potential sorting motifs, LL and YxxΦ, were 
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coupled to a CM5 sensor chip. The in vitro 
interaction was analyzed using a BIAcore 2000 
(BIAcore AB) as described (53). Briefly, AP-1 
and AP-2 were purified from porcine brain and 
injected at 100 nM in buffer A (20 mM HEPES 
pH 7.0, 150 mM NaCl, 10 mM KCl, 2 mM MgCl2, 
0.2 mM dithiothreitol) at a flow rate of 20 µl/min. 
Association (2 min) was followed by dissociation 
(2 min) during which buffer A was perfused, and 
the equilibrium constant (KD) was determined 
(53). 
Statistical Analysis - Statistical significance was 
assessed by using the student’s t test. Differences 
in means were considered statistically significant 
when p was < 0.05. 
 
RESULTS 
Differential localization of N-terminal and C-
terminal domains of E3/49K during early and late 
times of infection - Previous studies using an 
antibody against the E3/49K cytoplasmic tail (anti-
49Kct) showed that E3/49K is localized in the ER, 
the Golgi/TGN, early endosomes and the plasma 
membrane at steady state (32,37). To address the 
fate of the large N-terminal ectodomain and the 
full-length protein we raised the antiserum anti-
49K-N and mAb 4D1 directed to this domain (32). 
In the early phase of infection co-staining with 
antibodies to the N-terminal domain and the C-
terminus revealed a large overlap (Fig. 1A, 12h 
p.i). By contrast, in the late phase of infection (36h 
p.i.) no co-localization was visible with the 
exception of a prominent perinuclear structure 
(Fig. 1B; merge, yellow) that also stained for the 
TGN marker TGN46 (see below, Fig. 2C), 
implying that E3/49K was still intact in the TGN. 
In the early phase the E3/49K C-terminus showed 
only limited overlap with LAMP-2, a marker for 
late endosomes (LE)/lysosomes (Fig. 1C) whereas 
in the late phase it was present  in many peripheral 
vesicles that were positive for this marker (Fig. 
1D). By contrast, the N-terminal domain/full 
length molecule was rarely detected in 
LE/lysosomes either early or late after infection 
(Fig. 1E and F). Thus, E3/49K C-terminal 
fragments accumulate in late 
endosomes/lysosomes at late times of infection 
whereas the N-terminal domain/full length 
molecule is either largely excluded from these 
compartments or immediately degraded. Taken 
together, this indicates that the C-terminal 
fragments and the full-length E3/49K protein may 
follow distinct trafficking pathways.  
 
Evidence for E3/49K recycling to the TGN - The 
prominent perinuclear structure positive for both 
the N- and C-terminal domains of E3/49K was 
identified as the TGN by colocalization with 
TGN46, a marker for the TGN (Fig. 2C and 2E). 
We next investigated whether or not the strong 
TGN staining of E3/49K at steady-state 
represented newly synthesized E3/49K molecules 
en route to the cell surface or E3/49K recycled 
from the cell surface via early endosomes, a 
pathway demonstrated for TGN46. To this end, 
Ad19a-infected SeBu cells were treated from 12-
18 h post-infection with cycloheximide (CHX) to 
block further protein synthesis. Subsequently, the 
localization of E3/49K was compared to that of 
TGN46 (Fig. 2). After 6 h treatment with CHX the 
perinuclear staining of the N-terminal E3/49K 
domain was drastically diminished (Fig. 2, N-
term; compare panels B with A and F with E). 
This contrasts with the C-terminal staining which 
was only slightly reduced (Fig. 2, C-term; 
compare panels B with A and D with C), similar to 
the limited changes noted for TGN46 under these 
two conditions (Fig. 2, compare panels D with C 
and F with E). The rapid CHX-mediated depletion 
of E3/49K molecules containing the N-terminal 
ectodomain indicated that these represented newly 
synthesized full-length E3/49K molecules whereas 
the (largely) CHX-resistant C terminus positive 
species represented predominantly C-terminal 
fragments of E3/49K that had been recycled to the 
TGN presumably from the plasma membrane. To 
confirm the presence of full-length E3/49K in the 
TGN we pursued triple labeling experiments 
staining for both N- and C-termini of E3/49K as 
well as the TGN followed by secondary Abs 
linked to three distinct dyes. In A549 cells infected 
with Ad19a both the N-terminus and C-terminus 
of E3/49K were present in the TGN (Fig. 2G) with 
a slight trend of the C-termini being in more 
peripheral areas of the TGN. When Ad19a-
infected SeBu cells were treated with the 
lysosomotropic agent chloroquine for 3 h to inhibit 
acidification, a considerable fraction of E3/49K C-
termini were found together with TGN46 in 
peripheral vesicles (Fig. 2H CHQ). Considering 
that TGN46 is known to recycle from the cell 
surface to the TGN via EE (54,55), these data 
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suggest that chloroquine inhibits recycling to the 
TGN (56,57) trapping both molecules in EE. Thus, 
the two proteins appear to utilize at least in part 
overlapping trafficking pathways. Taken together, 
we conclude that the prominent steady-state 
localization of E3/49K in the Golgi/TGN is due 
primarily to newly synthesized full-length proteins 
en route to the cell surface and to C-terminus-
positive E3/49K species that might include both 
full-length and C-terminal fragments recycled 
from the cell surface via endosomes.  
 
The cytoplasmic tail of E3/49K binds to clathrin 
adaptor complexes in vitro - To determine  
whether the dileucine motif LL and the tyrosine-
based motif, YNHM in the cytoplasmic tail are 
involved in sorting and intracellular trafficking of 
E3/49K we initially used Surface Plasmon 
Resonance (SPR) spectroscopy to examine 
whether immobilized peptides representing the 
WT cytoplasmic tail or mutated versions of it (Fig. 
3, mutations highlighted in red) would bind to 
purified clathrin adaptor complexes AP-1 and AP-
2 in vitro. Indeed a significant interaction with 
both AP-1 and AP-2 was detected (Fig. 3, WT). 
Replacing the tyrosine by alanine (YA) inhibited 
binding to AP1 and AP2 by 2.7-fold and 1.6-fold, 
respectively. Mutation of the dileucine motif 
(LLAA) reduced AP-1 binding by 8.3-fold and 
AP-2 binding by 2.5-fold. Interaction was 
completely abolished when both motifs were 
mutated (YA/LLAA). Thus, both motifs can be 
recognized by AP-1 and AP-2 in vitro, although 
the interaction with the dileucine motif seems to 
be more critical than that of the YxxΦ motif.  
 
Increased cell surface expression of E3/49K 
proteins with mutated cytoplasmic tails - To test 
the function of these putative sorting motifs in 
vivo, stable A549 cell lines were established that 
constitutively expressed E3/49K proteins with 
either or both of the motifs mutated by alanine 
substitution (YA and LLAA). Additionally, the 
influence on trafficking of the entire cytoplasmic 
tail was examined by creating the E3/49K mutant 
∆CT that lacked all cytoplasmic residues except 
the stop-anchor sequence RKR. Relative cell 
surface expression of each molecule was 
determined by flow cytometry comparing the 
mean fluorescence intensities (MFIs) of multiple 
clones in the absence (cell surface) and presence 
of the detergent saponin (representing mostly 
internal E3/49K). To allow a comparison of clones 
with different E3/49K protein expression levels 
the MFI ratios (surface/intracellular) were 
analyzed rather than the absolute surface MFIs. 
For WT E3/49K clones this MFI ratio ranged from 
0.24-0.29 (Fig. 4), suggesting that the majority of 
E3/49K is localized inside of the cell, consistent 
with the immunofluorescence analysis (Fig. 1). 
This is in contrast to a typical cell surface 
molecule, such as HLA where the majority is 
found on the cell surface. E3/49K mutants 
YA/LLAA and ∆CT, lacking both motifs, showed 
2.9-fold and 2.3-fold higher ratios, respectively. 
Thus a larger proportion of E3/49K is displayed on 
the cell surface in the absence of these C-terminal 
tail motifs. This is statistically significant as 
compared to WT whereas the difference between 
the two mutants is not. For the single mutant 
LLAA the ratio was also increased (1.7-fold), 
whereas the YA mutants were comparable to WT 
(0.9-fold). Thus, a higher proportion of YA/LLAA 
and ∆CT, and to a lesser extent LLAA were 
expressed on the cell surface as compared to WT 
and the YA mutant of E3/49K. These data are 
consistent with the notion that the LL motif is 
important for E3/49K internalization.  
The role of the E3/49K cytoplasmic tail motifs in 
its localization was investigated further by 
confocal microscopy using transient transfection 
of E3/49K expression plasmids. The YA/LLAA 
mutant exhibited much stronger cell surface 
staining with anti-C terminal antibody than either 
the WT or other mutants (Fig. 5A). Generally, all 
mutants lacking the LL motif seemed to be present 
in substantially smaller vesicles, whereas the 
phenotype of the YA mutant was basically 
identical to WT. In contrast, cell surface staining 
for the ectodomain was considerably weaker (Fig. 
5A, YA/LLAA), and only modestly increased 
from WT as was also the case for the ∆CT and 
LLAA mutants. Within the cell, the number of 
vesicles containing the N-terminal domain was 
considerably reduced in all LL mutant molecules 
compared to staining with anti-49Kct, indicating 
that the ectodomain may have been removed at the 
cell surface or during endocytosis. These data 
support the idea that the dileucine motif may be 
involved in endocytosis of E3/49K.  
To trap E3/49K molecules in early endosomes 
after internalization from the cell surface and 
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prevent their potential degradation we also assayed 
their localization in chloroquine-treated cells. For 
wild-type, YA and LLAA mutant E3/49K, most 
vesicles stained with both N-terminal and C-
terminal  antibodies and appeared swollen under 
these conditions (Fig. 5B, chloroquine), hence 
representing predominantly full-length E3/49K 
species in endosomes. In contrast, for both the 
YA/LLAA and ∆CT mutants, N-terminal and C-
terminal 49K antibodies gave distinct staining 
patterns. apart from a few swollen vesicular 
structures in the centre of the cell that stained with 
both antibodies and are likely to represent the 
TGN (Fig. 5B). For YA/LLAA the C-terminal 
antibody labeled the plasma membrane and many, 
mostly smaller, intracellular vesicles. By contrast, 
staining with the antibody against the ectodomain 
detected hardly any intracellular vesicles apart 
from the centrally located presumed TGN 
structure and surface staining was less prominent. 
For the ∆CT mutant N-terminal staining was 
similar to the double mutant but the surface 
display was further enhanced; C-terminal antibody 
cannot recognize the ΔCT mutant. Taken together, 
these data indicate that internalization of the 
YA/LLAA and the ∆CT mutants of E3/49K was 
indeed strongly impaired and that the ectodomain 
may be cleaved at the cell surface. In the absence 
of functional trafficking motifs C-terminus 
specific antibodies label apart from the cell surface 
intracellular vesicles that are largely not swollen 
and thus may represent mostly full-length E3/49K 
species en route to the cell surface. Conversely, 
this suggests that full-length E3/49K lacking 
transport motifs are not efficiently internalized and 
are not present in endo/lysosomes at steady state. 
 
Impact on E3/49K processing of pharmacological 
agents affecting acidification, lysosomal 
proteases, glycosylation and intracellular 
trafficking - To investigate whether proteolytic 
processing of E3/49K could be manipulated and to 
gain first insight into the compartments where 
cleavage of E3/49K was occuring, Ad19a-infected 
A549 cells were pulse-labeled with [
35
S]-
methionine (0) and chased for 2 h and 6 h in the 
presence of various pharmacological agents. 
Detergent extracts (lysate) were used to monitor 
intracellular processing and generation of the C-
terminal fragment by immunoprecipitation with 
antibodies against the cytoplasmic tail, whilst 
concomitantly the release of the ectodomain into 
the supernatant was followed with N-terminal 
specific antibodies (32). In mock-treated cells the 
secreted ectodomain was detected in the 
supernatant after 2 h of chase while three low 
molecular weight C-terminal species (h1-3) were 
visualized in the lysates with h3 being typically a 
minor species. After 6 h of chase, h1 was hardly 
visible anymore while the smallest fragment h3 
had considerably increased in intensity (Fig. 6A, 
lanes 2-4). This indicates that following the initial 
cleavage(s) releasing the N-terminal ectodomain 
the C-terminal fragment(s) are further trimmed. 
This second cleavage seems to occur in a different 
compartment from that of the initial cleavage, 
since h3 appeared later (at > 2-3 h of chase) than 
fragments h1 and h2 which became visible at ~1 h 
of chase.  
When cells were treated with leupeptin, an 
inhibitor of lysosomal cysteine and serine 
proteases (Fig. 6A, lanes 8-13) fragment h3 was 
not detected (compare lanes 10 and 4), suggesting 
that h3 is generated by a lysosomal cysteine or 
serine protease. Consistent with this notion very 
little if any h3 was detected after treatment with 
agents that elevate the pH of endosomal/lysosomal 
compartments, such as chloroquine (Fig. 6B, lanes 
1-6) or bafilomycin A1 an inhibitor of the vacuolar 
type H(+)-ATPase (Fig. 6C, lanes 1-6). Treatment 
with 10mM ammonium chloride also reduced the 
amount of h3 but was less effective (Fig. 6B, lanes 
7-12). Upon treatment with the Na
+
 ionophore 
monensin (58) that affects primarily the TGN 
cisternae and late processing events, such as 
terminal glycosylation and proteolytic cleavages, 
but may also impact on other acidic compartments, 
such as lysosomes, h3 was also not produced (Fig. 
6C, lanes 7-12). Collectively, these results 
substantiate the hypothesis that the second 
cleavage that gives rise to the h3 fragment is pH-
dependent and takes place in LE/lysosomes. 
Surprisingly, none of these treatments used to 
perturb intracellular processing prevented initial 
cleavage and secretion of E3/49K (Fig. 6A-C). 
Only some minor effects on carbohydrate 
processing were noted. Chloroquine and to a lesser 
extent ammonium chloride reduced the kinetics of 
carbohydrate processing while monensin impaired 
glycan modification as indicated by the minimally 
increased molecular weight of the chased E3/49K. 
Such an effect of monensin has been previously 
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noted for a number of glycoproteins and is thought 
to be due to either direct inhibition of the 
modifying enzymes or inhibition of further 
transport through the medial/trans-Golgi apparatus 
(58). The latter can be excluded in this case since 
E3/49K is still secreted in the presence of 
monensin (Fig. 6C, lanes 10-12). The impact of 
these agents on the efficiency of sec49K secretion 
was quantitatively assessed by determining the 
amount of radioactive sec49K released after 6 h of 
chase using phosphoimager analysis and relating 
this to the amount of intracellular E3/49K 
synthesized after the pulse (radioactivity in the 
high molecular weight forms at 0 h chase). Taking 
into account the relative frequency of methionine 
in sec49K versus full-length E3/49K (4 vs 5) 80% 
of the radioactivity was expected to be in the N-
terminal ectodomain and 20% in the cytoplasmic 
tail fragments. Potential differences in the 
affinities of the anti-49Kct and anti-N antibodies 
were ignored. Unexpectedly, chloroquine and 
bafilomycin A1 treatment increased the fraction 
secreted considerably, from 25-30% in untreated 
cells to ~53% and 54%, respectively, while 
leupeptin promoted secretion only slightly to 
~36% and ammonium chloride had no significant 
effect. In line with previous reports (58), monensin 
reduced secretion slightly by ~25% (data not 
shown).  
Strikingly, treatment with tunicamycin, an 
inhibitor of N-glycosylation, and brefeldin A 
(BFA), which causes the redistribution/absorption 
of Golgi membranes and proteins into the ER (59) 
blocking transport to the cell surface, abolished 
proteolytic processing of E3/49K altogether. In the 
presence of these drugs neither low molecular 
weight C-terminal fragments were detected in the 
lysates nor was the ectodomain sec49K found in 
the supernatant (Fig. 6D). As expected, 
tunicamycin reduced the relative molecular mass 
of E3/49K from 80-100 kDa to 49 kDa (49K-
CHO). Under these conditions a prominent band 
of a size consistent with non-glycosylated Ad19a 
E3/19K (an ER-resident protein; 19K-CHO)  was 
co-precipitated with E3/49K lacking N-linked 
sugars, suggesting that E3/49K was retained in the 
ER probably due to misfolding. This was 
confirmed by immunofluorescence studies 
showing that in the presence of tunicamycin 
E3/49K colocalizes with the ER marker 
calreticulin in transfected cells (Fig. 6E) and with 
E3/19K in infected cells (Fig. 6F). Thus, 
consistent with the timing of the appearance of the 
C-terminal fragments, cleavage occurs in a post-
ER compartment. This does not seem to be the 
Golgi/TGN since E3/49K was still cleaved and 
secreted in the presence of monensin. However, 
the redistribution of Golgi membranes into the ER 
and the block of transport by BFA prevented 
cleavage and sec49K secretion even though 
limited glycan processing was evident as indicated 
by the marginal molecular weight shift of E3/49K 
during the chase period (Fig. 6D, lane 7-9). Taken 
together, we conclude that proteolytic processing 
of E3/49K requires transport through the 
medial/trans-Golgi apparatus and occurs in a post-
Golgi/TGN compartment. 
 
E3/49K cleavage does not require trafficking 
motifs and involves matrix metalloproteases at the 
cell surface - We next investigated whether the 
above post-Golgi compartment where ectodomain 
cleavage putatively occurs might be the plasma 
membrane. To this end, two cell clones of WT and 
each E3/49K mutant were treated with BFA for 4 
h and subsequently the level of E3/49K surface 
staining was quantified by flow cytometry using 
antibodies against the ectodomain. Strikingly, cell 
surface staining was rapidly lost when transport of 
newly synthesized protein to the cell surface was 
blocked by BFA (Fig. 7A). Only between ~5% 
and 15% of the E3/49K levels remained at the cell 
surface after 4 h. By contrast, the impact of BFA 
on typical cellular plasma membrane protein levels 
was very modest, reducing their expression in 
comparison to mock-treated cells only to ~75% for 
HLA, ~86% for Fas and 80% for the EGFR (Fig. 
7A). Thus, the rapid loss of E3/49K and its 
mutants from the cell surface in spite of a partial 
or complete removal of putative endocytosis 
motifs supports the notion that rapid loss reflects 
proteolytic cleavage on the cell surface.  
A major class of proteases involved in cleavage 
of ectodomains on the cell surface, a process 
named shedding, comprises matrix 
metalloproteases (MMPs). To investigate their role 
in sec49K release wild-type E3/49K expressing 
cells (K27S) and cells expressing E3/49K devoid 
of all sorting motifs (YA/LLAA32) were treaterd 
with various MMP inhibitors and release of 
sec49K into the medium monitored by the 
sensitive T lymphocyte binding assay (32). 
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Secretion of sec49K in WT cells was reduced to 
only ~30% using the broadly acting MMP 
inhibitors BB-94 and CT1746 (Fig. 7B). 
Strikingly, a similar reduction was observed for 
GI254023X, an inhibitor of “a distintegrin and 
metalloproteinase” (ADAM) 10 and 17. These 
inhibitory effects were further increased for cells 
expressing the E3/49K mutant YA/LLAA lacking 
putative endocytosis motifs, consistent with the 
notion that such a molecule would exhibit a 
prolonged residence time on the cell surface and 
hence the impact of an inhibitor acting on a cell 
surface protease is expected to be more severe. 
Concomitantly, inhibitor treatment resulted in a 
substantial increase in E3/49K cell surface 
expression which was further enhanced for mutant 
YA/LLAA lacking the motifs (data not shown). 
If cleavage occurs at the cell surface, it is 
predicted that it is independent of the presence of 
sorting motifs and should occur by default. Indeed, 
the small C-terminal E3/49K fragments visualized 
upon metabolic labelling were detected in all cell 
lines except those that express the mutant lacking 
the cytoplasmic tail and hence has lost the 
antibody epitope (Fig. 7C). Thus, the primary 
cleavage resulting in ectodomain secretion is 
independent of the sorting motifs. Moreover, 
whilst the migration of the low molecular weight 
fragments in each mutant differs slightly (Fig. 7C, 
lanes 2-9), it is obvious that only WT and YA 
proteins produced significant amounts of the 
smallest h3 fragment (arrow). Thus, the generation 
of this fragment which occurs subsequent to the 
primary h1/2 products requires the LL but not the 
YxxΦ motif, consistent with the importance of the 
endo/lysosomal compartment for this secondary 
cleavage (Fig. 6). 
 
Increased secretion/ectodomain shedding of 
sec49K in E3/49K proteins lacking the LL motif 
The impact of the E3/49K sorting motifs on 
glycan maturation kinetics and sec49K secretion 
was further investigated by pulse-chase analysis of 
two individual transfectant clones with similar 
expression levels. No significant differences in the 
processing kinetics between WT and mutant 
E3/49K proteins were observed (data not shown). 
As examples, immunoprecipitations of the WT 
and mutants YA/LLAA and ∆CT that lack both 
known transport motifs are shown (Fig. 8A). The 
carbohydrate processing of WT (lanes 3-5), 
YA/LLAA (lanes 9-11) and ∆CT mutants (lanes 
15 –17) was very similar. By 45 min of chase all 
E3/49K molecules had been converted to the 
higher molecular weight form containing mature 
carbohydrates, although detection of the double 
mutant by anti-49Kct was inefficient (lanes 9-11) 
due to reduced recognition of the mutated 
cytoplasmic tail. Furthermore, the kinetics of 
sec49K secretion, first visible in the supernatant at 
45 min of chase, was also not altered significantly 
between WT and mutant E3/49K proteins 
(compare lanes 6-8 with lanes 12-14 and 18-20). 
However, the amount of sec49K appeared to be 
increased in the YA/LLAA and ∆CT mutants 
(compare lanes 14 and 20 with lane 8). Therefore, 
we quantitatively assessed the extent of sec49K 
secretion for all mutants (two clones each) using 
pulse/chase analysis combined with 
phosphoimager analysis. For WT E3/49K an 
average of 21% was secreted. Setting this 
secretion of WT as 100%, sec49K secretion from 
the YA/LLAA and the ∆CT mutants was increased 
to ~350% while that of LLAA mutants was 3-fold 
enhanced (Fig. 8B). In contrast, secretion of the 
YA mutant was similar to WT. Secretion of WT 
protein was also drastically increased upon 
treatment of infected cells with chloroquine and 
bafilomycin A1 (4-fold and 3.5 fold, respectively; 
Fig. 8B).  
To obtain independent evidence for the amount 
of sec49K secreted in the different mutant cell 
lines we also used the Jurkat binding assay to 
quantify sec49K in the supernatant of mutant cells. 
One clone from WT and each mutant was selected. 
The amount of sec49K detected was normalized to 
the number of cells in the cell culture plate and the 
differential synthesis level that was assessed by 
intracellular staining of E3/49K in the presence of 
BFA (Fig. 8C). As can be seen, while the YA 
expressing cell clone secreted similar amounts of 
sec49K as WT over a 4-day period the amount of 
sec49K was approximately 2-fold higher in cell 
clones that lack the LL motif alone or in 
combination with the tyrosine-based motif. Thus 
the LL motif has a significant impact on shedding 
of the E3/49K ectodomain. 
Interestingly, the increased secretion of mutant 
E3/49K proteins correlated well with the increased 
cell surface ratio of these mutants (Fig. 4), 
consistent with the hypothesis that proteolytic 
cleavage occurs at the cell surface. To further test 
 10 
this hypothesis, we examined the fate of surface-
exposed E3/49K in cell lines expressing either WT 
or mutant E3/49K by incubating live cells with the 
E3/49K N-terminal antibody at 0 ˚C and then 
warmed to 37 ˚C for different periods of time prior 
to fixation and immunofluorescence detection 
(Fig. 9). At time zero (no incubation at 37 ˚C), 
WT, YA/LLAA and ΔCT cells each showed 
exclusively surface labelling, as expected. Within 
10 min at 37 ˚C, much of the fluorescent WT 
E3/49K had been internalized into smaller vesicles 
in the periphery, some of which co-localized with 
TGN46. At 45 min the vesicles appeared slightly 
larger and in a more central location, partially 
overlapping with the TGN (Fig. 9 and data not 
shown). By contrast, neither of the mutant proteins 
showed any internalization, even after 45 min, yet 
the level of surface staining still diminished such 
that most cells became essentially unlabelled by 
45 min. Thus, this loss of E3/49K cell surface 
staining can only be explained by shedding, i.e. 
direct cleavage at the cell surface. Taken together 
the removal of the dileucine motif alone or in 
concert with the YxxΦ motif enhances secretion, 
presumably by impairing rapid endocytosis and 
subsequent transport to the TGN and 
LE/lysosomes. Consequently, this would lead to a 
prolonged exposure to the sheddase on the cell 
surface and hence a more efficient secretion.  
 
DISCUSSION  
The Ad19a E3/49K protein has been shown to 
exhibit a novel immunomodulatory mechanism for 
Ad E3 proteins. Unlike other E3 proteins it can 
modulate activities of leukocytes through secretion 
and binding to CD45 (32). Interestingly, this is not 
achieved by the synthesis of a genuine secreted 
protein but by synthesizing first a transmembrane 
glycoprotein that is subsequently proteolytically 
cleaved into a small membrane-integrated C-
terminal fragment and a large N-terminal 
ectodomain, sec49K that is shed (32,37). This 
processing pathway is associated with a complex 
subcellular distribution of E3/49K at steady state 
in the ER, the Golgi/TGN, early endosomes and 
on the cell surface (37).  
By mutating putative sorting motifs in the 
cytoplasmic tail of E3/49K and the combined use 
of antibodies against the ectodomain and the C-
terminus we investigated the role of these motifs 
for trafficking, proteolytic processing and 
secretion. The results are summarized in the model 
shown in Fig. 10. In the early phase of infection 
staining with antibodies against the cytoplasmic 
tail and the ectodomain overlaps greatly for the 
ER, Golgi/TGN, the plasma membrane and some 
internal vesicles that most likely represent EEs 
(37). The ER and the Golgi/TGN contain full-
length E3/49K that represents primarily newly 
synthesized protein en route to the cell surface. 
The apparent concentration of E3/49K in the TGN 
at steady-state may simply reflect the smaller 
membrane surface area of this compartment 
relative to others in the pathway; alternatively, the 
requirement for extensive modifications to be 
applied here may delay its exit. Collectively, the 
data suggest that E3/49K reaches the cell surface 
in an intact form, where it becomes cleaved by a 
sheddase (1). This cleavage does not appear to be 
very efficient as the molecule is clearly detectable 
on the cell surface by FACS. Upon internalization 
initiated by recognition of the LL motif by AP-2 a 
large proportion of the C-terminal fragment but 
also residual non-cleaved E3/49K is recycled from 
the cell surface via endosomes to the TGN from 
which they seem to be returned to the cell surface 
and re-exposed to the sheddase. This conclusion is 
based on the continuous staining of the TGN and 
vesicles with anti-49Kct antibody after inhibition 
of protein synthesis and the concomitant loss of 
ectodomain staining. It remains open whether 
internalized E3/49K species are also directly 
recycled to the cell surface from EEs or via 
recycling endosomes (REs; thin arrows in Fig. 10). 
During intracellular trafficking a smaller fraction 
of the C-terminal fragments may be continuously 
diverted to LE/lysosomes where these are cleaved 
a second time into the slightly smaller fragment h3 
by an acidophil leupeptin-sensitive protease (Fig. 
10; (2). The accumulation of C-terminal fragments 
in the LE might reflect selective trafficking 
relative to the uncleaved form, perhaps based on 
differential accessibility to adaptors due to 
conformation changes or differential acylation 
since E3/49K has a perfect acylation motif at the 
cytoplasmic tail/TMD border, but the observations 
may equally be explained simply by the continual 
loss of sec49K at the plasma membrane through 
successive trafficking cycles. In any case, 
trafficking of E3/49K to LE/lysosomes may only 
be a minor pathway since the great majority of 
full-length E3/49K and its C-terminal part are 
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clearly entering a recycling pathway to the TGN 
(Fig. 10 thick arrow) as demonstrated by the 
partial overlap of cell surface labeled E3/49K with 
the Golgi/TGN and the persistent staining with 
anti-49Kct after blocking protein synthesis. 
This complex trafficking pathway of E3/49K 
seems to be governed by sorting motifs in the 
cytoplasmic tail since cytoplasmic tail peptides 
were capable of binding to the clathrin adaptor 
complexes AP-1 and AP-2 in vitro in a motif-
dependent fashion (Fig. 3). Although the LL motif 
does not fit the consensus sequence of acidic 
[DE]xxxL[LI] dileucine signals recognized by AP-
1 and AP-2 or DxxLL motifs that are bound by 
Golgi-localised, γ-ear containing, ARF-binding 
proteins (GGAs), as the acidic residue is in 
position -2 in E3/49K (17), its mutation altered the 
subcellular distribution. Relative to their synthesis, 
mutant molecules lacking LL were expressed at 
higher levels on the cell surface compared to WT, 
consistent with a deficiency in endocytosis (Fig. 4 
and 5). A role for the dileucine motif in 
endocytosis was further supported by the 
drastically reduced presence of full-length 
YA/LLAA and ∆CT in swollen endosomal 
vesicles after chloroquine treatment (Fig. 5), the 
complete lack of endocytosis of surface labeled 
LL mutated E3/49K and a marked increase in 
sec49K secretion for all LL mutants. In contrast, 
mutation of the tyrosine motif had little effect in 
any of these assays (Fig. 7 and 8) suggesting that 
LL is the dominant internalization motif of 
E3/49K. Interestingly, the in vitro binding to AP-1 
was more affected by mutation of the motifs than 
binding to AP-2. Therefore, an alternative 
explanation might be that the dileucine controls a 
critical sorting step subsequent to endocytosis, e.g. 
in endosomes, as proposed for the mannose-6 
phosphate receptor 46 where LL was implicated in 
endocytosis and recycling to the TGN (60,61). 
Alternatively, LL may be responsible for diverting 
a fraction of E3/49K to LE/lysosomes, thereby 
reducing the amount of E3/49K available for 
secretion. The mechanism how the C-terminal 
fragments are diverted to LE/lysosomes and 
accumulate there remains open, but we speculate 
that targeting depends on prior ectodomain 
cleavage. Considering the localization of AP-1 at 
the TGN and EEs, and AP-2 at the plasma 
membrane (43), we propose that AP-2 mediates 
internalization primarily through binding to the LL 
motif whilst AP-1 is involved in the recycling of 
E3/49K species from EEs to the TGN (Fig. 10).  
The precise role of the YxxΦ motif for 
trafficking remains elusive. While in vitro binding 
of E3/49K cytoplasmic tail peptides to AP-1 and 
AP-2 was in a similar range as for other cargo 
protein peptides (41, 44, 53), and was affected by 
the YA substitution (Fig. 3), no phenotype was 
noted upon expression of the corresponding 
E3/49K mutant in cells. It is conceivable that the 
close proximity (6 amino acids) of the YxxΦ motif 
to the transmembrane domain may prevent 
recognition by the adaptor proteins in vivo since 
there is a minimum separation of 7 residues among 
other proteins in which this motif is active and in one 
of these, LAMP-1, reduction to less than 6 residues 
led to altered sorting (78). Also, the sequence 
context of the motif is not particularly favorable 
for a transport motif and the amino acid M is 
rarely found in the bulky hydrophobic position in 
such motifs (17). On the other hand, the tyrosine 
mutation in addition to the LL mutation 
consistently gave a more robust phenotype, 
resulting in a higher surface/intracellular ratio, a 
stronger cell surface staining and an enhanced 
secretion as compared to the LL mutation alone. 
This suggests that the tyrosine-based motif and the 
LL motif act in concert. The YxxΦ motif might 
have a role in recycling to the TGN, as shown for 
one of the tyrosine motifs in TGN46 (56). We also 
cannot rule out a role of the YxxΦ motif for 
basolateral sorting in polarized epithelial cells, as 
shown for other proteins (62,63), or for sorting in 
specialized cell types such as dendritic cells. These 
antigen presenting cells are efficiently infected by 
Ad19a (38). Alternatively, YxxΜ may serve as a 
docking site for class I phosphatidylinositol 3-
kinases (PI3Ks), thereby impacting on endocytosis 
or signaling (or both) along the E3/49K trafficking 
pathway relevant for cell metabolism, cell 
survival/apoptosis or functions of immune cells 
(64-66).  
Our study provides strong evidence that 
ectodomain processing of E3/49K occurs at the 
plasma membrane. Firstly, drugs that prevent ER 
export of E3/49K or promote redistribution of 
membrane proteins from the Golgi into the ER 
blocked proteolytic processing and secretion of 
E3/49K, while monensin, which acts primarily on 
late TGN compartments, had no impact on either 
process, strongly suggesting that ectodomain 
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cleavage occurs in a post-Golgi compartment. 
Since full-length E3/49K reaches the cell surface 
in significant amounts (32) proteolytic processing 
in secretory vesicles (SV, Fig. 10) appears 
unlikely. Moreover, none of the lysosomotropic 
agents prevented cleavage, ruling out involvement 
of any endosomal/lysosomal compartment. In 
support of this conclusion mutation of either or 
both transport motifs did not prevent cleavage, 
indicating that no sorting step is required for 
cleavage. As ∆CT lacks all known sorting motifs it 
is expected to reach the cell surface by the default 
pathway allowing the ectodomain to be cleaved 
and secreted. Supporting this suggestion, BFA 
treatment caused a rapid loss of WT and mutant 
E3/49K cell surface expression. Moreover, in the 
mutant cell lines surface-labeled fluorescent 
E3/49K is lost within 10-45 min in the absence of 
any notable internalization (Fig. 9), strongly 
suggesting ectodomain cleavage occurs at the cell 
surface.  
We conclude that E3/49K cleavage is mediated 
by cellular sheddases of the MMP family (Fig. 
10). Inhibitors of MMPs acting primarily on the 
cell surface, including one targeting ADAM10 and 
ADAM17, reduced secretion of sec49K 
dramatically (Fig. 7B) while enhancing cell 
surface expression of E3/49K (data not shown). In 
line with this conclusion, increased cell surface 
expression of LL-mutated molecules correlated 
with increased secretion (Fig. 4 and Fig. 8). This 
can be explained by the increased residence time 
on the cell surface upon elimination of the putative 
endocytosis motif, allowing for a more efficient 
cleavage of E3/49K by such proteases acting at the 
cell surface. However, increased ectodomain 
shedding of these molecules may also be due in 
part to a lack of intracellular degradation normally 
mediated by these motif(s). In support of this 
notion, chloroquine and bafilomycin enhanced 
secretion (Fig. 8) although no substantial staining 
of the ectodomain with late endosomes/lysosomes 
was noted even in the presence of chloroquine  
Many secreted cellular proteins, including 
cytokines, cytokine receptors, and growth factors 
are initially synthesised as transmembrane proteins 
and are subsequently cleaved by sheddases (67), 
such as ADAMs, e.g. ADAM10 and ADAM17 
(67-69), so this pathway clearly has advantages 
under some circumstances. Frequently, the initial 
cleavage of the ectodomain is followed by a 
second, regulated intramembrane cleavage of the 
C-terminal fragment which may have additional 
functions. For example, the large ectodomain of 
the amyloid precursor protein (APP) (70,71) is 
shed by α- and β-secretases whereby α-secretase 
activity includes ADAMs (72), while 
intramembrane cleavage is carried out by γ-
secretase leading to amyloid-beta production 
(67,72). The second cleavage of Notch, another 
ADAM target, results in a fragment that modulates 
transcription. Interestingly, the smallest C-terminal 
E3/49K fragment h3 is clearly the result of a 
second cleavage of h1/h2 in LE/lysosomes (Fig. 
10; (2). The role of these C-terminal fragments, if 
any, remains elusive. Although our data indicate 
that the E3/49K ectodomain is shed by MMPs, 
including ADAM10 or ADAM17, more detailed 
studies using knockdown of individual MMPs are 
necessary to identify conclusively the relevant 
protease. Together with a precise analysis of the 
cleavage products this knowledge will be very 
useful for putative exploitation of sec49K as 
recombinant viral-derived immunomodulator for 
therapeutic applications (73). 
It is puzzling as to why E3/49K is initially 
synthesized as a membrane protein only to give 
rise to a secreted ectodomain with binding activity 
to CD45 (32). Ectodomain shedding as opposed to 
direct secretion might be easier to regulate than 
conventional uncontrolled secretion. This could be 
relevant to limit the immune response to E3/49K. 
Alternatively, this points to an additional hitherto 
unknown function for the membrane-bound form 
or the C-terminal E3/49K stub on the cell surface 
or intracellularly. Cell surface E3/49K did not 
inhibit NK lysis,(32) however its activity on other 
leukocytes was not tested. The cycling of E3/49K 
between plasma membrane, endosomes and TGN 
would be consistent with it re-routing and 
degrading cellular target proteins as shown for 
CMV M6 (74) or the Ad E3/10.4-14.5K complex 
(24,49,75). The latter down-regulates various 
apoptosis receptors and the EGFR whereby the 
two E3 proteins involved contain each a sorting 
motif in its cytoplasmic tail. However, to date we 
have not detected any significant interaction/co-
precipitation of membrane-bound E3/49K with 
cellular proteins. An additional role of the C-
terminal portion would be consistent with the  
relatively long half-life and the high conservation 
of its sequence. The last 50 amino acids exhibit 84 
 13 
to 100% amino acid identity for different Ad types 
of species D, whereas that of the secreted N-
terminal domain (~ 383 amino acids) is 
considerably lower, ranging from ~36% to 55% 
(34,76). This N-terminal sequence diversity is 
consistent with the proposed recombination hot 
spot within E3/49K/CR1β, which seems to drive 
rapid evolution and diversification of sec49K (22). 
New evidence suggests that apart from the 
common interaction of species D E3/49Ks with 
CD45, this diversity results in differential, Ad 
type-specific interactions with various inhibitory 
receptors of the immune system which could be 
relevant for the disease-causing potential 
(Martinez-Martin and Gonzalez, Genentech, 
personal communication). Further research into 
the specific interactions of E3/49K molecules of 
different Ads will be crucial to understand their 
individual functions and potential relationship to 
disease. 
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FIGURE LEGENDS 
 
FIGURE 1. Differential localization of the ectodomain and the cytoplasmic tail of E3/49K in the 
Golgi/TGN and late endosomes/lysosomes during early and late phases of infection. Primary 
fibroblasts (SeBu) were infected with Ad19a and processed for confocal laser microscopy at 12 h or 36 h 
p.i., corresponding to the early and late phase of the infection cycle in these primary fibroblasts, 
respectively. The subcellular localization of E3/49K was analyzed with rabbit antiserum R25050 directed 
against the C-terminus (C-term, A-D) and antiserum R48-7B (anti-49K-N; E, F) followed by FITC-
labeled goat anti-rabbit IgG. For detection of the N-terminal part of E3/49K (N-term) the rat mAb 4D1 
was employed (A, B, middle panel). This was compared to the late endosomal/lysosomal marker LAMP-
2, using mouse mAb 2D5 (C-F, middle panel). Subsequent staining was done with Donkey anti-Rat-
Texas Red, and Donkey anti-mouse Rhodamine Red-X, respectively. One typical experiment of at least 
three is shown. 
 
FIGURE 2. The steady state localization of E3/49K in the Golgi/TGN comprises newly synthesized 
uncleaved E3/49K as well as recycled C-terminal fragments that co-localize extensively with 
TGN46. Primary fibroblasts (SeBu) infected with Ad19a for 12 h were treated for 6 h with 50 µg/ml 
cycloheximide (CHX). Subsequently, cells were processed for confocal laser microscopy by staining 
E3/49K with anti-49Kct (A-D) and rat mAb 4D1 against the ectodomain (N-term; A, B, E, F). 
Golgi/TGN localization was determined by co-staining for the TGN marker TGN46 using either sheep 
polyclonal Abs (C, D, G, H) or rabbit polyclonal Abs (E, F) followed by FITC-labeled donkey anti-rabbit 
IgG or rhodamine-labeled donkey anti-sheep IgG, anti-rat IgG and anti-mouse IgG. For the triple labeling 
experiment (G) A549 cells infected with Ad19a for 9 h were fixed and stained with antibodies against 
TGN46 and the N- and C-termini of E3/49K. Secondary Abs were Alexa Fluor 488 labelled goat anti-rat 
IgG, Alexa Fluor 633 labelled goat anti-rabbit IgG and Alexa Fluor 594 labelled donkey anti-sheep IgG. 
Images are single optical sections. Each channel was imaged separately under single laser illumination to 
prevent cross-over, and overlayed using Leica confocal software. Scale bar 10 µm (H) Primary fibroblasts 
infected with Ad19a for 12 h were treated for 3 h with 100 µM chloroquine (CHQ) prior to staining with 
antibodies against TGN46 and anti-49Kct. The figure shows one typical experiment of three (A-F) and 
two (G, H), respectively. 
 
FIGURE 3. Efficient binding of clathrin adaptor proteins AP-1 and AP-2 to cytoplasmic tail peptides of 
E3/49K depends on the presence of the YxxΦ and LL motifs. The lower panel shows the different 
cytoplasmic tail peptides used for the surface plasmon resonance spectroscopy studies with putative 
sorting signals highlighted in bold. WT: wild-type; YA: mutant version with alanine substitution of the 
YxxΦ motif; LLAA: altered version with alanine substitution of the LL motif. YA/LLAA peptide with 
both motifs eliminated. Altered amino acids are shown in red. The equilibrium constants (KD) were 
determined in at least three independent experiments and are given in nM/l +/- StDev. The upper panel 
shows the response vs time in seconds for the incubation of the different peptides with purified AP-1. n. 
d.: not detectable 
 
FIGURE 4. Elimination of the LL motif in the cytoplasmic tail significantly enhances relative cell 
surface expression of E3/49K. A549 cell lines stably expressing wild-type E3/49K (WT) or mutants in 
which the LL and YxxΦ motif, respectively, in the cytoplasmic tail were mutated to AA (LLAA) and 
AxxΦ (YA). In YA/LLAA, both putative sorting motifs were mutated while ∆CT lacked the entire 
cytoplasmic tail except a basic RKR stop-transfer sequence. Expression on the cell surface and internally 
was quantitatively analyzed by flow cytometry in the absence and presence of the detergent saponin, 
respectively. By determining the ratio of cell surface vs intracellular MFIs rather than the absolute cell 
surface values E3/49K cell surface expression becomes independent of its general synthesis level in each 
transfectant clone. MFIs for cell surface and intracellular staining was determined in 4-6 independent 
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experiments for 2-5 isolated clones of which three are shown. Error bars indicate the standard deviation. 
A significant difference between cell lines expressing wild type and mutated E3/49K is indicated by an 
asterisk (*p<0.05). The difference in the ratios between double mutant YA/LLAA and ∆CT is not 
statistically significant.  
 
FIGURE 5. Removal of both putative sorting motifs enhances cell surface display of full-length 
E3/49K and C-terminal fragments and reduced their accumulation in swollen vesicles during 
chloroquine treatment. A549 cells were transiently transfected with pSG5 plasmids encoding WT and 
mutant E3/49K proteins as described in experimental procedures. Cells were treated with 100 µM 
chloroquine for 12 h  (B) or left untreated (A). After 36 h cells were processed for confocal laser 
microscopy. Staining was performed with rat mAb 4D1 directed against the N-terminal ectodomain (αN) 
and rabbit serum R25050 against the C-terminus of E3/49K (αC-term) followed by Donkey anti-Rabbit 
IgG-FITC and Donkey anti-Mouse-Rhodamine Red-X. The figure shows a representative experiment out 
of three. 
 
FIGURE 6. Proteolytic processing and secretion of E3/49K in the presence of agents affecting 
glycosylation, endosomal/lysosomal proteases, the pH of intracellular compartments or trafficking. 
Ad19a-infected A549 cells were labelled with [
35
S]-methionine for 30 min (0) and chased with medium 
containing non-radioactive methionine for 2 h and 6 h. Subsequently, detergent extracts were prepared 
(lysate) and E3/49K immunoprecipitated with anti-49Kct whilst the supernatant was processed and 
immunoprecipitated with anti-49K-N as described (32). The different agents indicated on top were 
included both in the starvation medium and the following incubations: (A) mock treated, with the same 
medium changes but without inhibitors (lanes 2-7) and leupeptin (200 µM, lanes 8-13); (B) bafilomycin 
A1 (100 nM, lanes 1-6) and monensin (10 µM, lanes 7-12); (C) chloroquine (100 µM, lanes 1-6) and 
ammonium chloride (10 mM, lanes 7-12); (D) tunicamycin (10 µg/ml, lanes 1-6) and brefeldin A (5 
µg/ml, lanes 7-12). The high molecular weight E3/49K species (49K) and the C-terminal fragments h1-h3 
are denoted on the right. E3/49K-CHO and E3/19K-CHO within the figure indicate the unglycosylated 
species of E3/49K and E3/19K. (E) Deglycosylated E3/49K colocalizes with the ER marker calreticulin 
upon tunicamycin treatment (3 h) in permanently transfected A549 cells expressing codon-optimized 
E3/49K (A549E3/49K-co15) and in infected cells (data not shown). Calreticulin was detected with a 
rabbit antiserum (Stressgen). (F) A549 cells were infected with Ad19a for 6 h, and treated for 3 h with 
tunicamycin (lower panels) or were mock-treated (DMSO; upper panels). Fixed cells were stained for 
E3/49K N-terminus and the ER-resident Ad19a protein E3/19K using rabbit antiserum R22612 and 
imaged as in Fig 2G. Scale bar 20µ. All experiments were carried out at least twice. 
 
 
FIGURE 7. E3/49K cleavage occurs independent of the putative transport motifs at the cell surface 
and is mediated by MMPs. (A) The mean fluorescence intensity of E3/49K WT or mutant clones 
(indicated below the figure) on the cell surface was determined by flow cytometry using mAb 4D1 after 
mock (black bars) and 4 h BFA treatment (5 µg/ml, white bars). Mean values and the StDev were 
calculated from 4-6 independent experiments except for Fas and EGFR expression that was measured 
only once. No BFA induced cytotoxicity or increased background staining was detectable within this 
timeframe. (B) Cells expressing WT E3/49K (K27S) or the double mutant YA/LLAA (clone 32) lacking 
all motifs were incubated with the broad spectrum matrix metalloprotease (MMP) inhibitors BB-94 and 
CT1746, and the more selective ADAM10 inhibitor GI254023X in 0.1 % DMSO (final concentration) for 
15-18h. Cells were also incubated with medium alone (mock) and 0.1% DMSO as solvent control 
(DMSO). Supernatants were harvested and centrifuged at 1,500g. Jurkat T cells (6x10
6
) were incubated 
with 200µl of supernatant followed by detection of sec49K binding using FACS analysis. The data show 
the mean plus StDev of 5 independent staining experiments and three independently produced 
supernatants. (C) Mutation of the transport motifs does not prevent initial cleavage but rather secondary 
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cleavage. Transfected clones indicated on top expressing E3/49K WT and mutant proteins were 
metabolically labeled for 2 h. E3/49K was precipitated with anti-49Kct antiserum (lanes 1-11) and anti-
49K-N (lanes 12 and 13). The figure shows one out of two experiments. Only the relevant sections of the 
SDS-PAGE with the 80-100 kDa and 10-14 kDa E3/49K species are shown. The arrow marks the C-
terminal fragment h3. 
 
FIGURE 8. Elimination of the LL motif alone or in combination with the YxxΦ  motif enhances 
secretion. (A) The processing kinetics of WT and mutant E3/49K proteins was determined by a 30 min 
pulse with [
35
S]-methionine followed by a 45min and 180 min chase. E3/49K was precipitated from 
untransfected (mock), WT and YA/LLAA mutant cell lysates with anti-49Kct (lanes 1-5 and 9-11) and 
anti-49K-N from ∆CT mutant cell lysates (lane 15-17) and all supernatants (lanes 6-8, 12-14, 18-20). (B) 
The proportion of E3/49K secreted was quantitatively determined in a separate pulse (0.5 h) chase (4 h) 
experiment followed by immmunoprecipitation with anti-49K-N and SDS-PAGE. Bands corresponding 
to sec49K were quantified by phosphorimager analysis and related to the radioactivity in E3/49K high 
molecular weight species after the pulse that was defined as 100%. The maximum amount is secreted 
when 80% of the total E3/49K labeling is released as the cytoplasmic tail contains 20% of the total [
35
S]-
methionine labeling. Mean values were calculated from two independent experiments except for the 
values obtained upon chloroquine and bafilomycin A1 treatment which were derived from single 
experiments. Error bars indicate the StDev. A significant difference between mutants and wild type (WT) 
is indicated by asterisks (*p<0.05). (C) Enhanced lymphocyte binding activity (sec49K) is observed in 
supernatants of mutants lacking the LL motif. One clone from WT and each mutant was assessed for the 
efficiency of secretion as measured using the Jurkat T lymphocyte binding assay. Cells were cultured for 
4 days and the supernatant harvested and centrifuged. Three independently collected supernatants were 
analyzed for the presence of sec49K in at least four different experiments as described in Experimental 
Procedures. Error bars indicate the StDev. A significant difference between mutants and wild type (WT) 
is indicated by asterisks (*p<0.05). 
 
FIGURE 9. Surface fluorescence of mutated E3/49K is lost in the absence of any internalisation 
whilst WT is internalized. A549 cells stably expressing either WT, YA/LLAA mutant or ΔCT truncated 
E3/49K were surface-labelled on ice with E3/49K N-terminal mAb 4D1. Excess antibody was removed 
and then cells warmed to 37 ˚C and incubated for the times indicated, Upon fixation the location of pre-
bound antibody was then revealed by staining with secondary antibody, and imaged as in Fig 2G using 
the same settings throughout to ensure comparability of image intensity. Scale bar 25 µm. One 
representative experiment of at least two is shown. 
 
 
FIGURE 10. Model for E3/49K trafficking and proteolytic processing. At steady-state, E3/49K is 
found in the Golgi/TGN, at the plasma membrane and in early endosomes (EE). At the TGN, E3/49K 
seems to be packaged by default into secretory vesicles (SV), however, a diversion to an endosomal 
compartment (EE) prior to appearing on the cell surface can formally not be ruled out. Proteolytic 
cleavage (dotted arrows) releasing the N-terminal ectodomain most likely occurs at the cell surface 
through “shedding” by MMPs (1). The C-terminal fragment and a considerable fraction of uncleaved 
E3/49K appears to be endocytosed through interaction of the LL motif in the C-tail with AP-2 (thick 
arrows). Full length E3/49K may be sorted in the EE into a recycling pathway to the plasma membrane, 
either directly from EE or via the TGN or the recycling endosome (RE) for another round of cell surface 
transport possibly involving AP-1. A minor pathway may direct E3/49K or predominantly the 
cytoplasmic tail fragments to late endosomes (LE) and lysosomes (Lys), where further proteolytic 
processing of h1/2 to h3 takes place (3). For further details and references see the text. The extent of the 
proposed transport pathway is indicated by the thickness of the arrows. 
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